These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 27091119)

  • 41. Managing paediatric acute severe ulcerative colitis according to the 2011 ECCO-ESPGHAN guidelines: Efficacy of infliximab as a rescue therapy.
    Aloi M; D'Arcangelo G; Capponi M; Nuti F; Vassallo F; Civitelli F; Oliva S; Pagliaro G; Cucchiara S
    Dig Liver Dis; 2015 Jun; 47(6):455-9. PubMed ID: 25733340
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: a Korean multicenter retrospective study.
    Lee KM; Jeen YT; Cho JY; Lee CK; Koo JS; Park DI; Im JP; Park SJ; Kim YS; Kim TO; Lee SH; Jang BI; Kim JW; Park YS; Kim ES; Choi CH; Kim HJ;
    J Gastroenterol Hepatol; 2013 Dec; 28(12):1829-33. PubMed ID: 23829336
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Compassionate access anti-tumour necrosis factor-α therapy for ulcerative colitis in Australia: the benefits to patients.
    Costello SP; Ghaly S; Beswick L; Pudipeddi A; Agarwal A; Sechi A; O'Connor S; Connor SJ; Sparrow MP; Bampton P; Walsh AJ; Andrews JM;
    Intern Med J; 2015 Jun; 45(6):659-66. PubMed ID: 25732268
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Changes in cytokine profile may predict therapeutic efficacy of infliximab in patients with ulcerative colitis.
    Sato S; Chiba T; Nakamura S; Matsumoto T
    J Gastroenterol Hepatol; 2015 Oct; 30(10):1467-72. PubMed ID: 25968585
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis.
    Gibson DJ; Heetun ZS; Redmond CE; Nanda KS; Keegan D; Byrne K; Mulcahy HE; Cullen G; Doherty GA
    Clin Gastroenterol Hepatol; 2015 Feb; 13(2):330-335.e1. PubMed ID: 25086187
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis.
    Maser EA; Deconda D; Lichtiger S; Ullman T; Present DH; Kornbluth A
    Clin Gastroenterol Hepatol; 2008 Oct; 6(10):1112-6. PubMed ID: 18928936
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetics of infliximab in children with moderate-to-severe ulcerative colitis: results from a randomized, multicenter, open-label, phase 3 study.
    Adedokun OJ; Xu Z; Padgett L; Blank M; Johanns J; Griffiths A; Ford J; Zhou H; Guzzo C; Davis HM; Hyams J
    Inflamm Bowel Dis; 2013 Dec; 19(13):2753-62. PubMed ID: 24193155
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Assessment of induction therapy with infliximab in children with moderate to severe ulcerative colitis: a multi-center study.
    Szychta M; Wiernicka A; Dądalski M; Landowski P; Klincewicz B; Karolewska-Bochenek K; Czaja-Bulsa G; Jarocka-Cyrta E; Korczowski B; Sladek M; Kierkus J
    Dev Period Med; 2016; 20(3):205-211. PubMed ID: 27941190
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Review article: dose optimisation of infliximab for acute severe ulcerative colitis.
    Hindryckx P; Novak G; Vande Casteele N; Laukens D; Parker C; Shackelton LM; Narula N; Khanna R; Dulai P; Levesque BG; Sandborn WJ; D'Haens G; Feagan BG; Jairath V
    Aliment Pharmacol Ther; 2017 Mar; 45(5):617-630. PubMed ID: 28074618
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Infliximab for pediatric patients with ulcerative colitis: a phase 3, open-label, uncontrolled, multicenter trial in Japan.
    Tajiri H; Arai K; Kagimoto S; Kunisaki R; Hida N; Sato N; Yamada H; Nagano M; Susuta Y; Ozaki K; Kondo K; Hibi T
    BMC Pediatr; 2019 Oct; 19(1):351. PubMed ID: 31607268
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort Study.
    Ma C; Beilman CL; Huang VW; Fedorak DK; Wong K; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    Can J Gastroenterol Hepatol; 2016; 2016():2079582. PubMed ID: 27478817
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tumor necrosis factor-mediated disposition of infliximab in ulcerative colitis patients.
    Berends SE; van Steeg TJ; Ahsman MJ; Singh S; Brandse JF; D'Haens GRAM; Mathôt RAA
    J Pharmacokinet Pharmacodyn; 2019 Dec; 46(6):543-551. PubMed ID: 31489538
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of the therapeutic efficacy and safety between tacrolimus and infliximab for moderate-to-severe ulcerative colitis: a single center experience.
    Nuki Y; Esaki M; Asano K; Maehata Y; Umeno J; Moriyama T; Nakamura S; Matsumoto T; Kitazono T
    Scand J Gastroenterol; 2016; 51(6):700-5. PubMed ID: 26818468
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Infliximab as rescue therapy in hospitalised patients with steroid-refractory acute ulcerative colitis: a long-term follow-up of 211 Swedish patients.
    Sjöberg M; Magnuson A; Björk J; Benoni C; Almer S; Friis-Liby I; Hertervig E; Olsson M; Karlén P; Eriksson A; Midhagen G; Carlson M; Lapidus A; Halfvarson J; Tysk C;
    Aliment Pharmacol Ther; 2013 Aug; 38(4):377-87. PubMed ID: 23799948
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Infliximab in pediatric ulcerative colitis: two-year follow-up.
    Mamula P; Markowitz JE; Cohen LJ; von Allmen D; Baldassano RN
    J Pediatr Gastroenterol Nutr; 2004 Mar; 38(3):298-301. PubMed ID: 15076630
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis.
    Adedokun OJ; Sandborn WJ; Feagan BG; Rutgeerts P; Xu Z; Marano CW; Johanns J; Zhou H; Davis HM; Cornillie F; Reinisch W
    Gastroenterology; 2014 Dec; 147(6):1296-1307.e5. PubMed ID: 25173754
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis.
    Su C; Salzberg BA; Lewis JD; Deren JJ; Kornbluth A; Katzka DA; Stein RB; Adler DR; Lichtenstein GR
    Am J Gastroenterol; 2002 Oct; 97(10):2577-84. PubMed ID: 12385442
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Genes associated with intestinal permeability in ulcerative colitis: changes in expression following infliximab therapy.
    Toedter G; Li K; Sague S; Ma K; Marano C; Macoritto M; Park J; Deehan R; Matthews A; Wu GD; Lewis JD; Arijs I; Rutgeerts P; Baribaud F
    Inflamm Bowel Dis; 2012 Aug; 18(8):1399-410. PubMed ID: 22223479
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Infliximab Exposure-Response Relationship and Thresholds Associated With Endoscopic Healing in Patients With Ulcerative Colitis.
    Vande Casteele N; Jeyarajah J; Jairath V; Feagan BG; Sandborn WJ
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1814-1821.e1. PubMed ID: 30613004
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial.
    Laharie D; Bourreille A; Branche J; Allez M; Bouhnik Y; Filippi J; Zerbib F; Savoye G; Nachury M; Moreau J; Delchier JC; Cosnes J; Ricart E; Dewit O; Lopez-Sanroman A; Dupas JL; Carbonnel F; Bommelaer G; Coffin B; Roblin X; Van Assche G; Esteve M; Färkkilä M; Gisbert JP; Marteau P; Nahon S; de Vos M; Franchimont D; Mary JY; Colombel JF; Lémann M;
    Lancet; 2012 Dec; 380(9857):1909-15. PubMed ID: 23063316
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.